Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
Showing 51 news results
April 24, 2026
Healio: FDA Grants Fast Track Designation to KT-621 for Moderate to Severe Eosinophilic Asthma
April 1, 2026
Dermatology Times: 85% of Biologic-Eligible AD Patients Left Behind — Can KT-621 Reach Them?
December 8, 2025
STAT News: Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
December 8, 2025
Endpoints News: Kymera’s Dupixent-in-a-pill impresses in closely-watched early eczema readout
December 8, 2025
Barron’s: Kymera Therapeutics Stock Heads for Record. Why Investors Are Excited About Its Anti-Inflammatory Drug.
September 19, 2025
Dermatology Times: KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 Degrader
Featured Presentations & Publications
September 17, 2025
KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Presentation
October 27, 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
American College of Rheumatology (ACR) 2025